Contineum Therapeutics (CTNM) Earnings Analysis
Contineum Therapeutics (CTNM) has no confirmed upcoming earnings date. Last quarter (2026-03-05) it beat with EPS -0.49 USD vs -0.5 USD est (+2%). It has beaten estimates in 2/3 recent quarters (67%). Trailing P/E -7.55.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does CTNM next report earnings?
No confirmed upcoming earnings date is currently scheduled for CTNM. This page updates as the calendar is published.
CTNM earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-05 | -0.49 USD | -0.5 USD | +2% | Beat |
| 2025-10-30 | -0.45 USD | -0.58 USD | +22.4% | Beat |
| 2025-03-06 | -0.56 USD | -0.44 USD | -27.3% | Miss |
Beat rate: 2/3 (67%) over reported quarters with consensus data.
CTNM valuation and analyst view
| Trailing P/E | -7.55 |
|---|---|
| Trailing EPS | -1.56523 USD |
| Price / book | 2.20 |
| Dividend yield | 0.00% |
| Market cap | 0.55B |
| Analyst consensus | Buy (2 buy / 1 hold / 0 sell) |
| Avg price target | 16 USD |
Related research pages
Frequently asked questions
When is Contineum Therapeutics (CTNM)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for CTNM. This page updates as the calendar is published.
Did CTNM beat earnings last quarter?
In its 2026-03-05 report, CTNM posted EPS of -0.49 USD versus a -0.5 USD estimate — a beat of 2%.
What is CTNM's earnings track record?
Over the last 3 reported quarters with consensus data, CTNM beat estimates 2 times (67%).
What is CTNM's current P/E ratio and EPS?
CTNM trades at a trailing P/E of -7.55 on trailing EPS of -1.5652256167581875 USD.
What do analysts rate CTNM?
Analyst consensus is "Buy" across 3 ratings (0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 16 USD.